SCHEMBL16335409

SCHEMBL16335409

Cc1ccnc(Oc2ccc(-c3c(C)c(=O)[nH]c(=O)n3C)cc2)c1Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30362261 1.00 DRD1 (1.00) DRD1
SCHEMBL16337708 0.86 DRD1 (1.00) DRD1
SCHEMBL16335994 0.84 DRD1 (1.00) DRD1
SCHEMBL15698790 0.80 DRD1 (0.75) DRD1
SCHEMBL17201639 0.80 DRD1 (1.00) DRD1
SCHEMBL22402233 0.79 DRD1 (1.00) DRD1
SCHEMBL18490007 0.79 DRD1 (1.00) DRD1
SCHEMBL15666428 0.79 DRD1 (1.00) DRD1
SCHEMBL17212927 0.78 DRD1 (1.00) DRD1
SCHEMBL23874197 0.78 DRD1 (0.64) DRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317713-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2024-09-26 US claimed
EP-3421462-B1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2023-04-05 EP claimed
US-10421744-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2019-09-24 US claimed
US-20190002439-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2019-01-03 US claimed
EP-3421462-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS Pfizer Inc (US) 2019-01-02 EP claimed
US-10093655-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2018-10-09 US claimed
US-20180037571-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2018-02-08 US claimed
US-9527831-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2016-12-27 US claimed
EP-3013813-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS Pfizer Inc. (US) 2016-05-04 EP claimed
US-20150005313-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2015-01-01 US claimed
WO-2014207601-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2014-12-31 WO claimed
US-20260125364-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2026-05-07 US disclosed
US-20240317713-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2024-09-26 US disclosed
US-11964961-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2024-04-23 US disclosed
EP-3421462-B1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2023-04-05 EP disclosed
US-20150175573-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2015-06-25 US disclosed
US-20150005313-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2015-01-01 US disclosed
US-20150005313-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2015-01-01 US disclosed
US-20150005313-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2015-01-01 US disclosed
WO-2014207601-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2014-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125364-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS HTR6, HTR3C, OPRD1 DRD1 37/4885
US-11964961-B2 Heteroaromatic compounds and their use as dopamine D1 ligands DRD2, DRD1, HTR1D DRD1 2/4885
US-10421744-B2 Heteroaromatic compounds and their use as dopamine D1 ligands DRD1, SNCA, DRD2 DRD1 1/4885
US-20190002439-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS DRD1, SNCA, DRD2 DRD1 1/4885
US-20240317713-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS DRD2, DRD1, HTR1D DRD1 2/4885
US-10093655-B2 Heteroaromatic compounds and their use as dopamine D1 ligands DRD1, SNCA, DRD2 DRD1 1/4885
US-20150005313-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS SNCA, DRD1, DRD2 DRD1 2/4885
US-20150175573-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS DRD2, DRD1, HTR1D DRD1 2/4885
US-20180037571-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS DRD1, SNCA, DRD2 DRD1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.